IP Library Granted Patent US 7,695,933
Granted Patent B2
US 7,695,933 · App. 11/058,924 · Granted Apr 13, 2010

SM38 nucleic acid molecules

Assignee: Trudeau Institute, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,695,933
App. No.
11/058,924
Granted
Apr 13, 2010
Kind
B2
Abstract

The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such compounds in the treatment of disorders involving CD38 modulated cell migration. Additionally, the invention relates to the isolation and characterization of a CD38 homologue from the parasitic flatworm, Schistosoma mansoni.

Claims (7)

1. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the SM38 amino acid sequence of FIG. 13A (SEQ ID NO: 5).

2. The isolated nucleic acid molecule of claim 1 comprising the SM38 nucleic acid sequence of FIG. 13A (SEQ ID NO: 1).

3. An isolated nucleic acid molecule comprising a nucleotide sequence that hybridizes over the full length to the nucleotide sequence of claim 2 in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.1×SSC/0.1% SDS at 68° C.

4. An isolated nucleic acid molecule comprising a nucleotide sequence that hybridizes over the full length to the plasmid pCR2.1-TOPO:SM38 5-18 (ATCC Deposit No: PTA-3780), or plasmid SK:SM38LC12 (ATCC Deposit No:PTA3781), in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.1×SSC/0.1% SDS at 68° C.

5. A recombinant expression vector comprising the nucleic acid molecule of claims 1 - 3 or 4 .

6. A recombinant cell comprising the nucleic acid molecule of claims 1 - 3 or 4 .

7. A method of producing a SM38 protein comprising growing a recombinant cell comprising the nucleic acid molecule of claims 1 - 3 or 4 such that the encoded SM38 protein is expressed by the cell and recovering the expressed SM38 protein (SEQ ID NO: 5).

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 24, 2012
From: TRUDEAU INSTITUTE, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027756/0112 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2007
From: LUND, FRANCES E; RANDALL, TROY D; PARTIDA-SANCHEZ, SANTIAGO
To: TRUDEAU INSTITUTE, INC.
Reel/Frame 019941/0019 →
Continuity (3)
Continuation In Part 0998261600 · Oct 17, 2001
Provisional Application 6024106500 · Oct 17, 2000
Related Publication 20060019308A1 · Jan 26, 2006